S. 4199 · 116th Congress
Prescription Drug Pricing Reduction Act of 2020
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 116th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
R
GrassleySponsor10 cosponsors · 10 R
R
Braun
SC
R
Collins
BC
R
Cassidy
SD
R
Daines
JE
R
Ernst
CH
R
Hyde-Smith
LM
R
Murkowski
MM
R
McSally
RP
R
Portman
DS
R
Sullivan9 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
This bill alters several programs and requirements relating to the prices of prescription drugs under Medicare and Medicaid.
What it does: CRS summary · Introduced in Senate · Jul 2, 2020
Prescription Drug Pricing Reduction Act of 2020
This bill alters several programs and requirements relating to the prices of prescription drugs under Medicare and Medicaid.
Among other things, the bill
- requires drug manufacturers to issue rebates to the Centers for Medicare & Medicaid Services (CMS) for certain drugs covered under Medicare for which the average manufacturer price increases faster than inflation;
- requires drug manufacturers to issue rebates to the CMS for discarded amounts of certain single-dose drugs covered under Medicare, based on information reported by providers;
- reduces the annual out-of-pocket spending threshold, and eliminates beneficiary cost-sharing above this threshold, under the Medicare prescription drug benefit;
- requires the CMS to publish certain information, as reported by pharmacy benefit managers (PBMs), relating to drug discounts and rebates, and payments between PBMs, health plans, and pharmacies;
- requires pass-through pricing models, and prohibits spread-pricing, for payment arrangements with PBMs under Medicaid; and
- increases the maximum rebate payable by drug manufacturers under the Medicaid Drug Rebate Program.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Prescription Drug Pricing Reduction Act of 2020
Latest action (Jul 2, 2020): Read twice and referred to the Committee on Finance. (Sponsor introductory remarks on measure: CR S4228)
Policy area: Health · Origin: Senate · Introduced: Jul 2, 2020
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.